Ablynx (EBR:ABLX) ABLYNX STRENGTHENS MANAGEMENT TEAM WITH THE APPOINTMENT OF DR DEBBIE LAW AS CHIEF SCIENTIFIC OFFICER
Ablynx (EBR:ABLX) GHENT, Belgium, 8 January 2009 - Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, announced today that it has appointed Dr Debbie Law, as its Chief Scientific Officer.










